tumour
Conditions
Interventions
health volunteers:Mirabegron p.o. 28days 100mg qd. or 200mg qd.
Tumor patients:Mirabegron p.o. 28days 100mg qd. or 200mg qd.
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Sign the informed consent before the test, and fully understand the content, process and possible adverse events. 2.For health volunteer:Both men and women, aged 18-65 years (including the boundary value) . 3.For tumour patients: Both men and women, aged 18-65 years (including the boundary value),Tumor bearing and not in the period of chemotherapy and targeted drug intervention. 4.Body mass index (BMI) is 19.0–26.0 kg/m2 (including critical values). 5.Proper bone marrow and organ function, as defined below: HB=80h/LANC=1.5*109/LPLT=50*109/L;ALT=3 ULN;AST=3 ULN;AST=3 ULN;TBIL=1.5 ULN 6.The expected survival is 3 months or more.
Exclusion criteria
Exclusion criteria: a.A history of tuberculosis infection. b.Patients with contraindications to mirabegron: allergic to mirabegron or any of its excipients; Patients with poorly controlled severe hypertension (SBP?180mmHg or/and DBP?110mmHg) c.Subjects with a history of fainting bloodfainting needle. d.Unwilling to stop drinking alcohol or using any alcoholic products during the study. e.Physical examination, electrocardiogram, laboratory examination, color ultrasound, chest orthogram, vital signs and study related examination abnormalities are clinically significant (based on the clinician's judgment). f.Female subjects who used long-acting estrogen or progesterone injections or implants within 6 months prior to the study. g.Women who are pregnant or breastfeeding. h.The subject may not be able to complete the study for other reasons or may not be able to participate in the study for other reasons judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The growth of brown adipose tissue; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood glucose/GTT; | — |
Countries
China
Contacts
Public ContactMinghua Ge
Outcome results
None listed